Category: 124038-36-4

On June 12, 2014, Rancati, Fabio; Linney, Ian published a patent.Application of 124038-36-4 The title of the patent was Preparation of compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity. And the patent contained the following:

The present invention relates to the preparation of heterocyclic containing quinuclidine ester compounds acting both as muscarinic receptor antagonists and β2 adrenergic receptor agonists. For example, compound I was prepared in several steps via the coupling of alc. II with acid III. The experimental process involved the reaction of Methyl 3-(1,3-dioxolan-2-yl)benzoate(cas: 124038-36-4).Application of 124038-36-4

The Article related to quinuclidine ester preparation muscarinic receptor antagonist, adrenergic receptor agonist quinuclidine ester, Alkaloids: Alkaloids Containing One Nitrogen Atom At A Bridgehead and other aspects.Application of 124038-36-4

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem

On June 12, 2014, Rancati, Fabio; Linney, Ian; Knight, Chris; Schmidt, Wolfgang published a patent.Synthetic Route of 124038-36-4 The title of the patent was Preparation of compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity. And the patent contained the following:

The present invention relates to compounds I [wherein: Q is a group of formula Q1, Q2 and Q3; Z is H or OH; Y is selected from A1B(CH2)n1A2CD(CH2)mE and A1CBC’D(CH2)pE, which are divalent groups; wherein A1 and A2 are independently absent or are selected from the group consisting of C1-6-alkylene, C3-8-cycloalkylene and C3-8-heterocycloalkylene optionally substituted by one or more substituents selected from the group consisting of C1-6-alkyl, aryl-(C1-6-alkyl) and heteroaryl-(C1-6-alkyl);]. [B is absent or is selected from the group consisting of C3-8-cycloalkylene, C3-8-heterocycloalkylene, arylene and heteroarylene, optionally substituted by one or more groups selected from halogens, CN, linear or branched C1-6-alkyl, linear or branched C1-6-haloalkyl, C1-6-alkoxy, aryl, aryl-(C1-6-alkyl), NR7R8 and heteroaryl;C and C’ are absent or are independently selected from the group consisting of oxygen, C(:O), OC(:O) and -C(OO)- or one of the following:]. [NR7C(:O), O(CH2)nO2C, N((CH2)nCO2R7)SO2, NR7(CH2)nO2C, CO2(CH2)nNR7C(:O), N(COR7)(CH2)nO2C, O2CCR7R8NHC(:O), NR7CONR7′(CH2)nO2C, C(:O)NR7(CH2)nO2C, (CH2)O2C, SO2NR7(CH2)nO2C, C12, N(SO2R7)(CH2)nO2C, C14; wherein R7, R7′ and R8 are independently H or selected from the group consisting of linear or branched C1-6-alkyl, C3-8-cycloalkyl, (C3-8-cycloalkyl)-(C1-6-alkyl), (C3-8-heterocycloalkyl)-(C1-6-alkyl), aryl and aryl-(C1-6-alkyl), optionally substituted by one or more substituents selected from the group consisting of C1-6-alkyl, C1-6-haloalkyl, halogen atoms, C1-6-alkoxy and C1-6-alkoxy;]. [D is absent or is selected from the group consisting of C1-6-alkylene, arylene, heteroarylene and C3-8-heterocycloalkylene, optionally substituted by one or more C1-6-alkyl groups; n, n’, m and p are independently O or an integer from 1 to 3; E is absent or is selected from O and OC(:O); G is arylene optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (:O), SH, NO2, CN and NH2;]. [R1 and R2 are independently H or selected from the group consisting of C1-6-alkyl and aryl, optionally substituted by one or more halogen atoms; M is NR3; R3 is H or C1-6-alkyl; R4 is a group of formula J1] acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists. Thus, 8-hydroxyquinolin-2-one derivative II was prepared from 3-hydroxybenzophenone via reductive amination with formamide; hydrolysis with HCl in MeOH; N-alkoxycarbonylation with di(tert-butyl) dicarbonate in CH2Cl2 containing EtN(CHMe2)2 followed by treatment with K2CO3 in MeOH; chromatog. resolution with CHIRALPAK® AD; etherification with 4-BrCH2C6H4CO2Me in MeCN containing K2CO3; hydrolysis with HCl in dioxane/MeOH; alkoxycarbonylation with (R)-quinuclidin-3-yl chloroformate (III) in pyridine;. Saponification with aqueous LiOH in THF; amidation with 3-(1,3-dioxolan-2-yl)propyl piperidine-4-carboxylate hydrochloride (IV·HCl) in DMF containing EtN(CHMe2)2 and HATU; deacetalation with aqueous HCl in THF; and reductive amination with of (R)-5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one hydrochloride (V·HCl) in MeOH containing NaBH(OAc)3 and AcOH. The present invention also relates to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmaceutical active ingredients. The receptor activity of I was determined [the Ki values (calculated from IC50 values by the Cheng and Prusoff equation) of most of the compounds of the examples are less than 10 nM in the M3 Receptor and in the β2 adrenoceptor radioligand binding assays]. The experimental process involved the reaction of Methyl 3-(1,3-dioxolan-2-yl)benzoate(cas: 124038-36-4).Synthetic Route of 124038-36-4

The Article related to muscarinic receptor antagonist, beta2 adrenergic receptor agonist, Alkaloids: Alkaloids Containing One Nitrogen Atom At A Bridgehead and other aspects.Synthetic Route of 124038-36-4

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem

On February 3, 2005, Fryszman, Olga M.; Lang, Hengyuan; Lan, Jiong; Chang, Edcon; Fang, Yunfeng published a patent.Application In Synthesis of Methyl 3-(1,3-dioxolan-2-yl)benzoate The title of the patent was Preparation of 5-membered heterocycles, in particular pyrazoles and imidazoles, as p38 kinase inhibitors. And the patent contained the following:

Title compounds I of [wherein R1 = H, acyl, P(:O)(OH)2; R2 = H, halo, (un)substituted alkyl, alkylthio, alkylsulfinyl, etc.; G = hetero/aryl, aralkyl, cycloalkyl, etc.; B = hetero/aryl; A = 5-membered ring containing one or two heteroatoms in the ring; D = CONH2 and derivatives, (un)substituted heteroaryl; R5 = H, halo, halo/thio/alkyl, OH and derivatives, alkyl/amino, etc.; R6 = H, halo, alkyl, alkoxy; and their pharmaceutically acceptable derivatives] were prepared as p38 kinase, including p38α and p38β kinase, inhibitors. Thus, reacting 3-hydrazino-N-methoxy-4-methylbenzamide with NaNO2 in the presence of SnCl2, and cyclization of the hydrazine with 2-(3-iodobenzoyl)-3-phenylaminoacrylonitrile gave II. Selected I displayed IC50 values <1 μM in a p38α kinase inhibition assay. I are useful for the treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, e.g. inflammatory disease, autoimmune disease, etc. The experimental process involved the reaction of Methyl 3-(1,3-dioxolan-2-yl)benzoate(cas: 124038-36-4).Application In Synthesis of Methyl 3-(1,3-dioxolan-2-yl)benzoate

The Article related to imidazole preparation p38 kinase inhibitor inflammation immunomodulator, antiinflammatory agent pyrazole preparation p38 kinase inhibition autoimmune disease, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Application In Synthesis of Methyl 3-(1,3-dioxolan-2-yl)benzoate

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem

On January 24, 2001, Alanine, Alexander; Buettelmann, Bernd; Heitz, Neidhart Marie-Paule; Jaeschke, Georg; Pinard, Emmanuel; Wyler, Rene published a patent.Application of 124038-36-4 The title of the patent was Triazole and imidazole derivatives, methods of preparation and use in treatment or prophylaxis of diseases caused by overactivation of respective NMDA receptor subtypes. And the patent contained the following:

The present invention relates to I wherein R1-R4 = H, CF3, OCF3, OCHF2, OCH2F, lower alkyl, lower alkoxy, halogen, hydroxy, Ph, benzyl, amino, nitro, pyrrol-1-yl, lower alkylsulfonyl, lower alkylthio, cyano or benzyloxy; or R2 and R3 may be together = O-(CH2)2-O-, -O-CH2-O-, -O-(CH2)2-, -(CH2)3- or CH:CH-CH:CH-; X = N:, imino with N possibly substituted, CH:; Y = -N:, :N-, imino with N possibly substituted, CH:; wherein one of X or Y has to be N; R5 = aminomethyl with N possibly substituted and to their pharmaceutically acceptable acid addition salts. The methods of preparation comprise cyclizing a carboxylic acid hydrazide with a benzenecarboximidamide hydrochloride or benzenecarboximidic acid ester to give a triazole; arylating a 4-iodo-2-phenylimidazole with a phenylboronic acid in the presence of Pd(PPh3)4 to give an imidazole; reducing II to the aminomethyl analog followed by di-N-alkylation using acyl chlorides and LiAlH4. These compounds may be used for the treatment or prophylaxis of diseases related to the N-methyl-D-aspartate (NMDA)-receptor-subtype selective blockers. Such diseases include acute forms of neurodegeneration caused, e.g., by stroke or brain trauma; chronic forms of neurodegeneration such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections, and diseases such as schizophrenia, anxiety, depression and acute/chronic pain. The experimental process involved the reaction of Methyl 3-(1,3-dioxolan-2-yl)benzoate(cas: 124038-36-4).Application of 124038-36-4

The Article related to nmda receptor blocking triazole imidazole derivative preparation, glutamate receptor nmda binding blocking triazole imidazole derivative preparation, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Application of 124038-36-4

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem

On February 5, 1992, Gilmore, Jeremy; Todd, Alec published a patent.Category: dioxole The title of the patent was Preparation of 5-[1-[(quinolylethenyl)benzyl]indol-7-yloxymethyl]tetrazoles and analogs as leukotriene antagonists. And the patent contained the following:

Title compounds [I; R = CR3R4C6H4YR5; R1 = H, halo, alkyl, alkoxy, etc.; R3, R4 = N, alkyl, (substituted) Ph, etc.; R5 = (substituted) heteroaryl; R6 = H, alkyl; 1 of R7, R8 = XR2 and the other = H; R2 = halo, cyano, CONH2, (protected) acid group, etc.; X = alkylene, oxyalkylene, etc.; Y = OCH2, CH2CH2, CH:CH, etc.] were prepared Thus, I (R1 = R6 = R8 = H) (II; R = H, R7 = OCH2CN) (preparation given) was condensed with quinolylethenylbenzyl chloride QCl and the product treated with Bu3SnN3 to give II (R = Q, R7 = 1H-tetrazol-5-ylmethoxy). I had pKb = 7-11 for dissociation of receptor inhibitor complexes in vitro. The experimental process involved the reaction of Methyl 3-(1,3-dioxolan-2-yl)benzoate(cas: 124038-36-4).Category: dioxole

The Article related to tetrazole quinolylethenylbenzylindolyloxymethyl preparation leukotriene antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Category: dioxole

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem

On August 25, 2020, Zhang, Chen; Zhu, Guozhi; Lu, Yonghua; Gao, Qiu; Liao, Yuting; Li, Yao; Yan, Pangke published a patent.Application of 124038-36-4 The title of the patent was Preparation of 8-hydroxy-1H-quinolin-2-one bridge derivatives as muscarinic receptor M3 antagonists and beta 2-adrenergic receptor agonists. And the patent contained the following:

The invention discloses preparation method of 8-hydroxy-1H-quinolin-2-one bridge ring derivatives, which has the characteristics of diverse structure and high activity. For example, the invention compound I was prepared via multi-step reaction of 4-[[3-[[(7-tertbutoxycarbonyl-3-oxa-7-azabicyclo[3.3.1]nonane-9-yl)oxocarbonylamino]-Ph methyl] phenoxy] methyl] benzoic acid. The invention compounds can be used as muscarinic receptor M3 antagonists and beta 2-adrenergic receptor agonists. The experimental process involved the reaction of Methyl 3-(1,3-dioxolan-2-yl)benzoate(cas: 124038-36-4).Application of 124038-36-4

The Article related to preparation hydroxyquinolinone muscarinic receptor m3 antagonist adrenergic receptor agonist, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Application of 124038-36-4

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem

On May 31, 1989, Young, Robert N.; Zamboni, Robert; Gauthier, Jacques Y.; Belley, Michel L. published a patent.Electric Literature of 124038-36-4 The title of the patent was Quinoline diacid derivatives useful as leukotriene antagonists, and their pharmaceutical compositions and use in medicaments. And the patent contained the following:

Title compounds I [R1 = H, halo, alkyl, alkenyl, alkynyl, CF3, SR2, S(O)R2, S(O)2R2, NR3R3, OR3, CO2R3, COR3, C(OH)R3R3, cyano,NO2, N3, (un)substituted Ph, PhCH2, PhCH2CH2, pyridyl; R2 = alkyl, alkenyl, alkynyl, CF3, (un)substituted Ph, PhCH2, PhCH2CH2; R3 = H, R2; R4 = H, halo, NO2, N3, cyano, SR2, NR3R3, OR3, alkyl, COR3; R5 = H, alkyl; Y = CR3:CR3, C:C, CO, NR3CO, CONR3, O, S, NR3, etc.; X1, X2 = complex chains, 1 or both containing C6H4, pyridine, or thiophene nucleus; Q1, Q2 = CO2R3, tetrazole, cyano, CHO, CH2OH, COCH2OH, etc.] are prepared for use as leukotriene antagonists (no data), and thereby as antiasthmatic, antiallergic, antiinflammatory, and cytoprotective agents. Thus, Wittig reaction of Me 2-[3-[2-(methoxycarbonyl)ethylthio]-3-(3-formylphenyl)propyl]benzoate (prepared in 6 steps) with [(7-chloroquinolin-2-yl)methyl]triphenylphosphonium bromide using BuLi in THF, and basic hydrolysis and salification of the product, gave [[[(chloroquinolinyl)ethenyl]phenyl](carboxyethylthio)propyl]benzoic acid di-Na salt II. The experimental process involved the reaction of Methyl 3-(1,3-dioxolan-2-yl)benzoate(cas: 124038-36-4).Electric Literature of 124038-36-4

The Article related to quinoline preparation leukotriene antagonist, antiasthmatic quinoline preparation, antiallergic quinoline preparation, antiinflammatory quinoline preparation, antiulcer quinoline preparation and other aspects.Electric Literature of 124038-36-4

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem

On August 20, 1992, Shim, Sang Chul; Doh, Chil Hoon; Youn, Young Zoo; Lee, Dong Yub; Lee, Seung Yub; Chae, Shin Ae published an article.Computed Properties of 124038-36-4 The title of the article was Carbonylation of bromobenzenes having aldehyde or protected aldehyde groups catalyzed by cobalt carbonyl(I). And the article contained the following:

3-BrC6H4CHR2 (R2 = O, OCH2CH2O, SCH2CH2CH2S) undergo carbonylation under 1 atm CO in R1OH (R1 = Me, Et, Pr, Bu) in the presence of Co2(CO)8, MeI, and K2CO3 to give 26-97% 3-(R2CH)C6H4CO2R1. The experimental process involved the reaction of Methyl 3-(1,3-dioxolan-2-yl)benzoate(cas: 124038-36-4).Computed Properties of 124038-36-4

The Article related to cobalt carbonyl catalyzed carbonylation bromobenzaldehyde, bromophenyldioxolane carbonylation cobalt carbonyl catalyzed, bromophenyldithiane carbonylation cobalt carbonyl catalyzed, formylbenzoate, alkoxycarbonylphenyldioxolane, alkoxycarbonylphenyldithiane and other aspects.Computed Properties of 124038-36-4

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem

On November 28, 1990, Young, Robert N.; Gauthier, Jacques Yves; Zamboni, Robert; Belley, Michel L. published a patent.Application In Synthesis of Methyl 3-(1,3-dioxolan-2-yl)benzoate The title of the patent was Preparation of diarylstyrylquinoline diacids as leukotriene antagonists. And the patent contained the following:

Title compounds I [R1 = 7-Cl, 7-MeO, 6-F3C, 7-F3C, 6-MeSO2, H, 6,7-Cl2; Y = CH:CH, CH2CH2, CH2O, CHMeCH2; A = HO2C(CH2)2S, Me2NCO(CH2)2S, 3-(HO2C)C6H4S, Me3CNHCO(CH2)2S, 4-carboxy-2-pyridyl, [(1-adamantylamino)carbonylethyl]thio, 1-tetrazol-5-ylmethylthio, etc.; B = 2-(HO2C)C6H4CH2CH2, 3-(HO2C)C6H4, 5-carboxy-2-thiophenyl, HO2CCH2CHMe(CH2)2, 6-carboxy-2-pyridyl, 2-(Me3CNHCO)C6H4S, 3-[(1-tetrazol-5-yl)methyl]phenyl, etc.] and their salts, useful as inhibitors of leukotriene biosynthesis, antiasthmatic, antiallergic, antiinflammatory, and cytoprotective agents (no data, assays described), are prepared I may also be used to treat erosive gastritis, inflammatory bowel disease, prevention of SRA-release (no data). To a suspension of [(7-chloroquinolin-2-yl)methyl]triphenylphosphonium bromide in THF was added BuLi, the reaction mixture was stirred at -78° and Me 2-[3-[2-(methoxycarbonyl)ethylthio]-3-(3-formylphenyl)propyl]benzoate [preparation from 3-(BrCH2)C6H4CN given] added, the mixture warmed to room temperature to give I [R1 = 7-Cl; Y = CH:CH; A = HO2C(CH2)2S; B = 2-(HO2C)C6H4CH2CH2] (II) as the di-Me ester, which in THF and MeOH was saponified to give II.2Na salt. A capsule, injectable suspension and tablet formulations comprising I are given. Pharmaceutical composition of I may comprise an addnl. active ingredient such as nonsteroidal antiinflammatory drug, peripheral analgesic, cyclooxygenase inhibitor, etc. The experimental process involved the reaction of Methyl 3-(1,3-dioxolan-2-yl)benzoate(cas: 124038-36-4).Application In Synthesis of Methyl 3-(1,3-dioxolan-2-yl)benzoate

The Article related to arylstyrylquinoline diacid preparation leukotriene antagonist, cytoprotection arylstyrylquinoline diacid, eye antiinflammatory arylstyrylquinoline diacid, antiasthmatic arylstyrylquinoline diacid, srsa inhibitor arylstyrylquinoline diacid preparation and other aspects.Application In Synthesis of Methyl 3-(1,3-dioxolan-2-yl)benzoate

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem